Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dronabinol/cannabidiol - GW Pharmaceuticals

Next Previous
Drug Profile

Dronabinol/cannabidiol - GW Pharmaceuticals

Alternative Names: GWP-42002/GWP-42003; GWP-42002:GWP-42003; GWP-42003/GWP-42002; GWP-42003:GWP-42002

Latest Information Update: 28 Sep 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GW Pharmaceuticals
  • Class Anti-ischaemics; Antineoplastics; Antipsychotics; Cannabinoids
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioblastoma; Schizophrenia
  • No development reported Cerebral ischaemia

Most Recent Events

  • 28 Sep 2022 No recent reports of development identified for phase-I development in Cerebral-ischaemia(In neonates) in United Kingdom
  • 05 May 2021 GW Pharmaceuticals has been acquired by Jazz Pharmaceuticals plc
  • 26 Aug 2019 Phase-I clinical trials in Cerebral ischaemia (In neonates) in United Kingdom (unspecified route) (GW Pharma pipeline august 2019)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top